Loading
institutionsInstitution
Imperial College Healthcare NHS Trust / Imperial College London Cancer Research
West London's academic cancer centre across Hammersmith and Charing Cross hospitals, partner with the ICR in the CRUK Convergence Science Centre.
Also called: Hammersmith HospitalCharing Cross Hospital
Overview
Imperial College Healthcare NHS Trust provides cancer services across Hammersmith, Charing Cross, St Mary's and Queen Charlotte's hospitals, including radiotherapy, haematology and stem cell transplantation, and the national gestational trophoblastic disease service at Charing Cross. Imperial College London's cancer research spans surgical innovation and imaging, gynaecological and hepatobiliary cancers, leukaemia and the MRC Laboratory of Medical Sciences at Hammersmith, and Imperial partners with The Institute of Cancer Research in the Cancer Research UK Convergence Science Centre, applying engineering and physical sciences to cancer. The trust is an Experimental Cancer Medicine Centre and part of the Imperial College Academic Health Science Centre.
Location
London, GB
Type
hospital · Imperial College London
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#266 · 24 points (0 Newsweek + 0 NCI + 24 from 12 linked objects) · ranking
- Gestational trophoblastic disease service
- Haematology and transplant
- Convergence science (engineering and cancer)
- Imaging and surgical innovation
Hashim U. Ahmed
Chair of Urology, Imperial College London
Prostate cancer diagnosticsFocal therapyHIFU
Led PROMIS, the trial that showed MRI can safely spare a quarter of men from prostate biopsy.
Julian Redhead
Trust Chief Executive, Imperial College Healthcare NHS Trust
Emergency medicineHospital managementUrgent and emergency care policy
Emergency medicine consultant who became Trust Chief Executive of Imperial College Healthcare NHS Trust in April 2026 after serving as its medical director.
Rakesh Heer
Chair of Urology and Consultant Urological Surgeon, Department of Surgery and Cancer, Imperial College London
Urological cancer surgerySurgical trialsProstate cancer screening
The Imperial urologist who is research lead on TRANSFORM and joint chief investigator of the trial asking whether taking the lymph nodes out during a prostatectomy does any good.
Shahid A. Khan
Professor of Practice (Hepatology), Imperial College London; Consultant Gastroenterologist and Hepatologist, Imperial College Healthcare NHS Trust; Chair, Cholangiocarcinoma-UK; Medical Adviser, AMMF
Cholangiocarcinoma epidemiologyHepatologyBiliary tract cancer guidelines
Hepatologist who documented the rise of cholangiocarcinoma in the UK and senior author of the 2023 British Society of Gastroenterology guideline that sets out how NHS teams should diagnose and manage it.
Similar pages
- InstitutionNottingham University Hospitals Cancer Centre (City Hospital)
Shares Precision-Panc, UK specialist HPB cancer centres, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag nhs-cancer-centre.
- InstitutionBristol Haematology and Oncology Centre
Shares UK specialist HPB cancer centres, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag nhs-cancer-centre.
- InstitutionLeicester Cancer Research Centre / University Hospitals of Leicester
Shares UK specialist HPB cancer centres, Pancreatic ductal adenocarcinoma and the tag nhs-cancer-centre.
- PersonAxel Behrens
Shares Cancer Research UK Convergence Science Centre, The Institute of Cancer Research, Cancer Research UK.
- InstitutionRoyal Free Hospital, Royal Free London NHS Foundation Trust
Shares AMMF, the Cholangiocarcinoma Charity, Precision-Panc, UK specialist HPB cancer centres, Pancreatic ductal adenocarcinoma.
- InstitutionKing's College Hospital, London
Shares AMMF, the Cholangiocarcinoma Charity, Precision-Panc, UK specialist HPB cancer centres, Pancreatic ductal adenocarcinoma.
- PersonCaroline Moore
Shares Hashim U. Ahmed, PROMIS, Prostate cancer.
- PersonMark Emberton
Shares Rakesh Heer, PROMIS, Prostate cancer.